A Study of WJ05129 in Advanced Malignant Solid Tumors

Exclusion criteria

• . Persons already known to be allergic to the active ingredients or excipients of the study drugs (WJ05129 tablets) ；
• . Patients previously treated with AURORA A kinase inhibitors (Alisertib, LY3295668, etc.) ；
• . Subjects who received a potent cytochrome CYP3A inhibitor or inducer within 14 days prior to initial administration and who needed to take these drugs throughout the study period;
• . Participate in other clinical studies within 4 weeks prior to initial administration, except during the follow-up period of observational (non-interventional) clinical studies or interventional studies;
• . Inability to swallow drugs orally, or having a condition that seriously affects gastrointestinal absorption as judged by the investigator;
• . Pregnant or lactating women;
• . Two or more malignancies within 5 years prior to first administration. Except for early stage malignant neoplasms (carcinoma in situ or stage I neoplasms) that have been eradicated, such as adequately treated carcinoma in situ of the cervix, basal cell or squamous cell carcinoma, etc.;
• . Underwent major surgery (as determined by the investigator) or was undergoing surgical recovery within 4 weeks prior to initial dosing. Anti-tumor chemotherapy (eluting for 6 weeks for the last chemotherapy with nitrosourea or mitomycin), radiotherapy, targeted therapy, hormone therapy, immunotherapy, or biotherapy within 4 weeks prior to initial administration. Receive anti-tumor or immunomodulatory TCM or Chinese adult medicine preparations within 2 weeks before the first administration;